{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T08:59:49Z","timestamp":1780477189773,"version":"3.54.1"},"reference-count":39,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical University of Varna\u2014Fund \u201cNauka\u201d","award":["19011\/29 May 2020"],"award-info":[{"award-number":["19011\/29 May 2020"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Cardiac injury caused by cancer therapy can be detected early using high-sensitivity cardiac troponins (hs-cTns), and this is crucial for preventing irreversible consequences. Clinically relevant issues regarding hs-cTns in oncologic settings\u2014such as reliable cut-off values, the optimal assessment timeframe, factors influencing their levels, and their prognostic ability in relation to functional echocardiographic parameters\u2014require further investigation. In this study, we aimed to examine the determinants of hs-cTnT variations during cancer therapy and the relationship between the biomarker and functional conventional echocardiographic parameters. Materials and Methods: We prospectively evaluated adult patients scheduled for chemotherapy for either breast or gastrointestinal cancers, excluding those with pulmonary and cardiac disorders. We enrolled 40 patients who underwent a minimum of one cycle of potentially cardiotoxic regimens containing at least one of the following agents: anthracyclines, cyclophosphamide, taxanes, 5-fluorouracil, platinum compounds, trastuzumab, or bevacizumab. We observed two-dimensional and tissue Doppler echocardiographic parameters and hs-cTnT levels for a median of 360 days (IQR 162, 478) following the start of chemotherapy. Results: The generalised estimating equation (GEE) analysis revealed significant elevations in hs-cTnT levels at three months (\u03b2 = 1.2; p = 0.005) and six months (\u03b2 = 2.3; p = 0.02) from baseline, influenced by anthracycline treatment (p = 0.009), renal function (p = 0.003), and increased cardiotoxicity risk (high: p = 0.013; medium: p &lt; 0.001). Elevated hs-cTnT levels independently predicted the deterioration of the LV longitudinal myocardial function, measured by the systolic tissue velocities, according to the GEE analysis. The receiver operating characteristic curve-derived hs-cTnT thresholds\u2014of 8.23 ng\/L and 8.08 ng\/L\u2014had a high negative predictive value for identifying Average and Lateral LVS\u2032 decreases, respectively. Conclusions: Our research supports the use of baseline and continuing hs-cTnT testing in cancer patients, showing the dependence of the biomarker on renal function, cardiovascular toxicity risk level, and anthracycline treatment. The hs-cTnT cut-off value of approximately 8 ng\/L may suggest a low probability of longitudinal myocardial function impairment and this observation needs further validation in larger cohorts.<\/jats:p>","DOI":"10.3390\/medicina61111911","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:50:48Z","timestamp":1761533448000},"page":"1911","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["High-Sensitivity Troponin T as a Prognostic Factor of Conventional Echocardiographic Parameters in Cancer Patients: A Prospective Observational Study"],"prefix":"10.3390","volume":"61","author":[{"given":"Svetoslava Elefterova","family":"Slavcheva","sequence":"first","affiliation":[{"name":"First Department of Internal Diseases, Faculty of Medicine, Medical University \u201cProf. Dr. Paraskev Stoyanov\u201d, 9000 Varna, Bulgaria"},{"name":"First Cardiology Clinic with Intensive Care Unit, St. Marina University Hospital, 9000 Varna, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevim Ahmed","family":"Shefket","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Faculty of Medicine, Medical University \u201cProf. Dr. Paraskev Stoyanov\u201d, 9000 Varna, Bulgaria"},{"name":"Clinical Laboratory, St. Marina University Hospital, 9000 Varna, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yana","family":"Bocheva","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Faculty of Medicine, Medical University \u201cProf. Dr. Paraskev Stoyanov\u201d, 9000 Varna, Bulgaria"},{"name":"Clinical Laboratory, St. Marina University Hospital, 9000 Varna, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atanas","family":"Angelov","sequence":"additional","affiliation":[{"name":"First Department of Internal Diseases, Faculty of Medicine, Medical University \u201cProf. Dr. Paraskev Stoyanov\u201d, 9000 Varna, Bulgaria"},{"name":"First Cardiology Clinic with Intensive Care Unit, St. Marina University Hospital, 9000 Varna, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse cardiac effects of cancer therapies: Cardiotoxicity and arrhythmia","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s12265-020-10042-3","article-title":"The Role of Biomarkers in Cardio-Oncology","volume":"13","author":"Ananthan","year":"2020","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","article-title":"Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy","volume":"109","author":"Cardinale","year":"2004","journal-title":"Circulation"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/14737159.2017.1283219","article-title":"Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy","volume":"17","author":"Cardinale","year":"2017","journal-title":"Expert. Rev. Mol. Diagn."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/ejhf.1631","article-title":"Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: A meta-analysis","volume":"22","author":"Michel","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e000403","DOI":"10.1161\/JAHA.113.000403","article-title":"High-Sensitivity Troponin Assays: Evidence, Indications, and Reasonable Use","volume":"3","author":"Sherwood","year":"2014","journal-title":"J. Am. Heart Assoc."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1136\/heartjnl-2015-307848","article-title":"Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality","volume":"101","author":"Pavo","year":"2015","journal-title":"Heart"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.amjcard.2011.01.006","article-title":"Early detection and prediction of cardiotoxicity in chemotherapy-treated patients","volume":"107","author":"Sawaya","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1200\/JCO.2015.65.7916","article-title":"Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients with Early-Stage Human Epidermal Growth Factor Receptor 2\u2013Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy","volume":"35","author":"Zardavas","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1002\/ehf2.14373","article-title":"Early diagnostic value of high-sensitivity cardiac troponin T for cancer treatment-related cardiac dysfunction: A meta-analysis","volume":"10","author":"Lv","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/ejhf.8","article-title":"Two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T in early detection and prediction of cardiotoxicity during epirubicine-based chemotherapy","volume":"16","author":"Kang","year":"2014","journal-title":"Eur. J. Heart Fail."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","article-title":"Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab","volume":"63","author":"Ky","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s10554-017-1082-6","article-title":"Assessment of biventricular systolic strain derived from the two-dimensional and three-dimensional speckle tracking echocardiography in lymphoma patients after anthracycline therapy","volume":"33","author":"Song","year":"2017","journal-title":"Int. J. Cardiovasc. Imaging"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"ehad655-2718","DOI":"10.1093\/eurheartj\/ehad655.2718","article-title":"The use of high sensitivity troponin T as a biomarker of anthracycline cardiotoxicity","volume":"44","author":"Bannister","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2174\/1871529X19666190912150942","article-title":"Prognostic Value of Cardiac Biomarkers Assessment in Combination with Myocardial 2D Strain Echocardiography for Early Detection of Anthracycline-Related Cardiac Toxicity","volume":"20","author":"Mahjoob","year":"2020","journal-title":"Cardiovasc. Hematol. Disord. Drug Targets"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/CIRCIMAGING.112.973321","article-title":"Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated with Anthracyclines, Taxanes, and Trastuzumab","volume":"5","author":"Sawaya","year":"2012","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e014708","DOI":"10.1161\/JAHA.119.014708","article-title":"Changes in Cardiovascular Biomarkers with Breast Cancer Therapy and Associations with Cardiac Dysfunction","volume":"9","author":"Demissei","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1097\/MJT.0000000000000930","article-title":"Elevations in High-Sensitive Cardiac Troponin T and N-Terminal Prohormone Brain Natriuretic Peptide Levels in the Serum Can Predict the Development of Anthracycline-Induced Cardiomyopathy","volume":"27","author":"Bisoc","year":"2020","journal-title":"Am. J. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1111\/echo.13704","article-title":"Early anthracycline-induced cardiotoxicity monitored by echocardiographic Doppler parameters combined with serum hs-cTnT","volume":"34","author":"Zhang","year":"2017","journal-title":"Echocardiography"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jcmg.2018.05.012","article-title":"Anthracycline Therapy Is Associated with Cardiomyocyte Atrophy and Preclinical Manifestations of Heart Disease","volume":"11","author":"Souza","year":"2018","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"suaf083-130","DOI":"10.1093\/eurheartjsupp\/suaf083.130","article-title":"Cardiac troponins and anthracycline cardiotoxicity: A sub study of the PROACT trial; are all assays made equal?","volume":"27","author":"Gilbert","year":"2025","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ehjci\/jev014","article-title":"Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"16","author":"Lang","year":"2015","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/ejechocard\/jep164","article-title":"Normative reference values for the tissue Doppler imaging parameters of left ventricular function: A population-based study","volume":"11","author":"Chahal","year":"2010","journal-title":"Eur. J. Echocardiogr."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s00392-007-0633-6","article-title":"Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults","volume":"97","author":"Dodos","year":"2008","journal-title":"Clin. Res. Cardiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1002\/ehf2.13515","article-title":"High-sensitivity cardiac troponin T determines all-cause mortality in cancer patients: A single-centre cohort study","volume":"8","author":"Finke","year":"2021","journal-title":"ESC Heart Fail."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/ehf2.14587","article-title":"Cardiological parameters predict mortality and cardiotoxicity in oncological patients","volume":"11","author":"Romann","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_29","first-page":"163","article-title":"High Sensitivity Troponin T as Complementary Modality for Determining Doxorubicin Regimen Cardiotoxicity in Non-Hodgkin Lymphoma Patients","volume":"12","author":"Prayogo","year":"2020","journal-title":"Adv. Pharm. Bull."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2147\/VHRM.S89842","article-title":"Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy","volume":"591","author":"Blaes","year":"2015","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1080\/1354750X.2018.1490969","article-title":"Possible mechanisms behind cardiac troponin elevations","volume":"23","author":"Hammarsten","year":"2018","journal-title":"Biomarkers"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: A position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"qyae081","DOI":"10.1093\/ehjimp\/qyae081","article-title":"Current use of echocardiography in cardio-oncology: Nationwide real-world data from an ANMCO\/SIECVI joint survey","volume":"2","author":"Barbieri","year":"2024","journal-title":"Eur. Heart J. Imaging Methods Pract."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1093\/ehjci\/jead170","article-title":"Current clinical use of speckle-tracking strain imaging: Insights from a worldwide survey from the European Association of Cardiovascular Imaging (EACVI)","volume":"24","author":"Sade","year":"2023","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Al Saikhan, L., Alobaida, M., Bhuva, A., Chaturvedi, N., Heasman, J., Hughes, A.D., Jones, S., Eastwood, S., Manisty, C., and March, K. (2020). Imaging Protocol, Feasibility, and Reproducibility of Cardiovascular Phenotyping in a Large Tri-Ethnic Population-Based Study of Older People: The Southall and Brent Revisited (SABRE) Study. Front. Cardiovasc. Med., 7.","DOI":"10.3389\/fcvm.2020.591946"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1161\/CIRCIMAGING.109.926022","article-title":"Reference Values and Distribution of Conventional Echocardiographic Doppler Measures and Longitudinal Tissue Doppler Velocities in a Population Free From Cardiovascular Disease","volume":"3","author":"Dalen","year":"2010","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e15877","DOI":"10.1111\/echo.15877","article-title":"Efficacy of mitral annular velocity as an alternative marker of left ventricular global longitudinal strain to detect the risk of cancer therapy-related cardiac disorders","volume":"41","author":"Ichikawa","year":"2024","journal-title":"Echocardiography"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1007\/s12282-017-0778-8","article-title":"High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients","volume":"24","author":"Kitayama","year":"2017","journal-title":"Breast Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/COC.0000000000000699","article-title":"A Prospective Study About Trastuzumab-induced Cardiotoxicity in HER2-positive Breast Cancer","volume":"43","author":"Sghaier","year":"2020","journal-title":"Am. J. Clin. Oncol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/11\/1911\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:30:25Z","timestamp":1761535825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/11\/1911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":39,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["medicina61111911"],"URL":"https:\/\/doi.org\/10.3390\/medicina61111911","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]}}}